Notice2022-26280

Statement of Organization, Functions, and Delegations of Authority

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
December 2, 2022

Issuing agencies

Health and Human Services DepartmentNational Institutes of HealthFood and Drug Administration

Abstract

The Secretary of Health and Human Services delegates to the National Institutes of Health (NIH) Director and the Food and Drug Administration (FDA) Commissioner the authorities vested in the Secretary of Health and Human Services under Section 3 of the Accelerating Access to Critical Therapies for ALS Act, as amended, to establish and implement a Public-Private Partnership for rare neurodegenerative diseases. These authorities may be redelegated. Exercise of this authority shall be in accordance with established policies, procedures, guidelines, and regulations as prescribed by the Secretary. The Secretary retains the authority to submit reports to Congress and promulgate regulations.

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 231 (Friday, December 2, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 231 (Friday, December 2, 2022)]
[Notices]
[Page 74154]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-26280]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Food and Drug Administration


Statement of Organization, Functions, and Delegations of 
Authority

AGENCY: National Institutes of Health and Food and Drug Administration, 
HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Secretary of Health and Human Services delegates to the 
National Institutes of Health (NIH) Director and the Food and Drug 
Administration (FDA) Commissioner the authorities vested in the 
Secretary of Health and Human Services under Section 3 of the 
Accelerating Access to Critical Therapies for ALS Act, as amended, to 
establish and implement a Public-Private Partnership for rare 
neurodegenerative diseases. These authorities may be redelegated. 
Exercise of this authority shall be in accordance with established 
policies, procedures, guidelines, and regulations as prescribed by the 
Secretary. The Secretary retains the authority to submit reports to 
Congress and promulgate regulations.

DATES: This authority delegation was approved by the Secretary of 
Health and Human Services on November, 29, 2022.

    Dated: November 29, 2022.
Xavier Becerra,
Secretary, Department of Health and Human Services.
[FR Doc. 2022-26280 Filed 12-1-22; 8:45 am]
BILLING CODE 4140-01-P


</pre></body>
</html>
Indexed from Federal Register on December 2, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.